To be able to measure the RoI on digital in pharma, it is necessary to understand customers as individuals and create newer segmentation based on these needs and interests. This calls for the NextGen RCPA of data collection and personalized communications that engage customers, based on which pharma must create customer experiences that matter to them. If your content does not scratch, where it itches the customers, digital or phygital, customers will not feel at home (comfortable, delighted, and wants more), which is what matters. Not a digital euphoria, which will soon die down as customers simply ignore it as they did when pharma launched a plethora of webinars.

Pharma Marketing & The Reinvention

Introducing the top 10 companies in top 10 therapy areas according to statistics published by AIOCD

Is Pharma Losing Good SalesPeople

Articles by Gopal Kishore, K. Hariram, Pankaj Mehrotra and Vivek Hattangadi

Managing Or Gardening? Great Managers Are Like Gardeners: Cultivating Growth in Teams

A great manager is not just a leader; they...

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Marketing

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Policies/Sales

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Strategy

Fostering Thought leadership in Healthcare

Top 25 Indian Pharma Companies by Revenues in 2024

India pharma is crucial for global healthcare, providing affordable...

Top 10 Indian Pharma – 2025

India's top 10 pharma companies by market capitalization, offering insights into...

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Thought Leadership
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

Draft Pharma Policy

Get an in-depth view into the Draft Pharma Policy - MedicinMan does a deep dive with the President of Karnataka Drug and Pharmaceutical Manufacturers Association

MedicinMan Indian Pharma Digital Adoption Survey

Smaller Indian pharma companies bore the strongest impact from...

FLUX – Indian Pharma in the Post VUCA World

Introduction For decades, leaders and organizations have relied on the...

Indian Pharmaceutical Innovation – Post TRIPS

It is the twentieth anniversary of the new patent act in January 2025. The post-patent (P20) era is a story of resilience, determination, and charting a course that set global ambitions, a story of finding opportunity in adversity. It is a story for case studies in business schools, in international studies, in global health efforts.

“Sales at Any Cost” is Not Sustainable in the Long Run

For commercial organisations, profits are important. But it cannot be 'at any cost' and certainly not at the cost of human life. As healthcare providers helping to mitigate the pain and misery of millions of human beings, we need to remember that charity begins at home.